Clinical trial
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
NCT05201638 is registered in ClinicalTrials.gov with Immunic AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
- Lead sponsor
- Immunic AG
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- January 12, 2022
- Completion date
- October 31, 2033
- Enrollment
- 1,100 (actual)
- Sites
- 101
Conditions
As the registry lists them; a condition with its own page is linked.